PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$12.87
0.16 (1.26%)
▲
5d:
+0.43%
30d:
+0.47%
90d:
-19.61%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PHAR appears deeply undervalued. Market expects -3.5% annual earnings decline despite 104% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: PHAR appears deeply undervalued. Market expects -3.5% annual earnings decline despite 104% recent earnings growth. Contrarian opportunity at discount to historical valuation.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $12.87, which is considered fair relative to its 30-day fair value range of $12.42 to $13.14. From a valuation perspective, the stock is trading at a discount (Forward PE: 196.5) compared to its historical average (218.5). Remarkably, the market is currently pricing in an annual earnings decline of 3.5% over the next few years. This pessimistic expectation contrasts with the company's recent 104.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PHAR is in a downtrend. Immediate support is located at $12.28, while resistance sits at $13.38.
Market Sentiment: PHAR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.35 (+166.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PHAR is in a downtrend. Immediate support is located at $12.28, while resistance sits at $13.38.
Market Sentiment: PHAR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.35 (+166.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$12.42 -
$13.14
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 166.9% below Wall St target ($34.35)
Trading Range Analysis
30-Day Trading Range
$12.42 -
$13.14
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$12.28
Resistance Level
$13.38
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
196.49
Wall Street Target
$34.35
(+166.9%)
Revenue Growth (YoY)
-8.4%
Earnings Growth (YoY)
104.2%
Profit Margin
3.3%
Valuation Discount vs History
-3.5% cheaper
PE vs Historical
196.5 vs 218.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.5%
(market-implied from PE analysis)
1-Year Target
$12.42
(-4%)
2-Year Target
$11.98
(-7%)
3-Year Target
$11.57
(-10%)
3-Yr Target (if PE normalizes)
(PE: 196→219)
$12.86
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 196.5, Growth: -71.6%)
$9.38
(+-27%)
Base:
(SPY PE: 21.8, Growth: -71.6%)
$1.04
(-92%)
Bear:
(PE: 18.5, Growth: -71.6%)
$0.88
(-93%)
📈
Valuation based on Current Earnings
Forward PE: 27.03 | Forward EPS (Implied): $0.48
Bull Case
$15.54
(+21%)
Analyst growth 15.0%, PE expands to 28.4
Base Case
$12.87
(0%)
Market implied 0.0%, PE stable at 27.0
Bear Case
$9.85
(-24%)
Severe decline -15.0%, PE contracts to 24.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 196.5 to 218.5
Stabilization Target:
$14.31
(+11.2%)
PE Expansion Potential:
+11.2%
Share & Embed Analysis
Last updated: June 24, 2026 4:03 AM ET
Data refreshes hourly during market hours. Next update: 5:03 AM
Data refreshes hourly during market hours. Next update: 5:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
